These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 24408067)

  • 21. Biochemical diagnosis of impaired left ventricular ejection fraction--comparison of the diagnostic accuracy of brain natriuretic peptide (BNP) and amino terminal proBNP (NT-proBNP).
    Mueller T; Gegenhuber A; Poelz W; Haltmayer M
    Clin Chem Lab Med; 2004 Feb; 42(2):159-63. PubMed ID: 15061354
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Meta-analysis of B type natriuretic peptide and N-terminal pro B natriuretic peptide in the diagnosis of clinical heart failure and population screening for left ventricular systolic dysfunction.
    Ewald B; Ewald D; Thakkinstian A; Attia J
    Intern Med J; 2008 Feb; 38(2):101-13. PubMed ID: 18290826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pericardial fluid and serum biomarkers equally predict ventricular dysfunction.
    Amjad S; Sami SA; Basir MN; Hameed K; Fujita M; Ahmad HR
    Asian Cardiovasc Thorac Ann; 2013 Apr; 21(2):160-5. PubMed ID: 24532613
    [TBL] [Abstract][Full Text] [Related]  

  • 24. N-terminal pro-b-type natriuretic peptide and left atrial function in patients with congestive heart failure and severely reduced ejection fraction.
    Prastaro M; Paolillo S; Savarese G; Dellegrottaglie S; Scala O; Ruggiero D; Gargiulo P; Marciano C; Parente A; Cecere M; Musella F; Chianese D; Scopacasa F; Perrone-Filardi P
    Eur J Echocardiogr; 2011 Jul; 12(7):506-13. PubMed ID: 21685193
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Plasma urotensin in human systolic heart failure.
    Ng LL; Loke I; O'Brien RJ; Squire IB; Davies JE
    Circulation; 2002 Dec; 106(23):2877-80. PubMed ID: 12460864
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-terminal protype-B natriuretic peptide and Doppler diastolic variables are incremental for risk stratification of patients with NYHA class I-II systolic heart failure.
    Dini FL; Fontanive P; Buralli S; Panicucci E; Andreini D; Conti U; De Tommasi SM
    Int J Cardiol; 2009 Aug; 136(2):144-50. PubMed ID: 18649955
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The preserved autonomic functions may provide the asymptomatic clinical status in heart failure despite advanced left ventricular systolic dysfunction.
    Kocaman SA; Taçoy G; Ozdemir M; Açıkgöz SK; Cengel A
    Anadolu Kardiyol Derg; 2010 Dec; 10(6):519-25. PubMed ID: 20952357
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of copeptin, B-type natriuretic peptide, and amino-terminal pro-B-type natriuretic peptide in patients with chronic heart failure: prediction of death at different stages of the disease.
    Neuhold S; Huelsmann M; Strunk G; Stoiser B; Struck J; Morgenthaler NG; Bergmann A; Moertl D; Berger R; Pacher R
    J Am Coll Cardiol; 2008 Jul; 52(4):266-72. PubMed ID: 18634981
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Relation of N-terminal pro-B-type natriuretic peptide to symptoms, severity, and left ventricular remodeling in patients with organic mitral regurgitation.
    Potocki M; Mair J; Weber M; Hamm C; Burkard T; Hiemetzberger R; Peters K; Jander N; Cron TA; Hess N; Hoffmann A; Gekeler H; Gohlke-Bärwolf C; Buser P; Mueller C
    Am J Cardiol; 2009 Aug; 104(4):559-64. PubMed ID: 19660612
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [BNP and echocardiography can predict the occurrence of acute cardiac decompensation during titration of bisoprolol in chronic systolic heart failure].
    Ben Driss A; Tabet JY; Meurin P; Weber H; Renaud N; Grosdemouge A; Bourmayan C
    Arch Mal Coeur Vaiss; 2007 Nov; 100(11):934-40. PubMed ID: 18209694
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term statin therapy in patients with systolic heart failure and normal cholesterol: effects on elevated serum markers of collagen turnover, inflammation, and B-type natriuretic peptide.
    Abulhul E; McDonald K; Martos R; Phelan D; Spiers JP; Hennessy M; Baugh J; Watson C; O'Loughlin C; Ledwidge M
    Clin Ther; 2012 Jan; 34(1):91-100. PubMed ID: 22154198
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparable increase of B-type natriuretic peptide and amino-terminal pro-B-type natriuretic peptide levels in patients with severe sepsis, septic shock, and acute heart failure.
    Rudiger A; Gasser S; Fischler M; Hornemann T; von Eckardstein A; Maggiorini M
    Crit Care Med; 2006 Aug; 34(8):2140-4. PubMed ID: 16763507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Atrial fibrillation and amino-terminal pro-brain natriuretic peptide as independent predictors of prognosis in systolic heart failure.
    Dini FL; Gabutti A; Passino C; Fontanive P; Emdin M; De Tommasi SM
    Int J Cardiol; 2010 Apr; 140(3):344-50. PubMed ID: 19128846
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The utility of inferior vena cava diameter and the degree of inspiratory collapse in patients with systolic heart failure.
    Besli F; Kecebas M; Caliskan S; Dereli S; Baran I; Turker Y
    Am J Emerg Med; 2015 May; 33(5):653-7. PubMed ID: 25704186
    [TBL] [Abstract][Full Text] [Related]  

  • 35. B-type natriuretic peptide can predict the medium-term risk in patients with acute heart failure and preserved systolic function.
    Valle R; Aspromonte N; Feola M; Milli M; Canali C; Giovinazzo P; Carbonieri E; Ceci V; Cerisano S; Barro S; Milani L
    J Card Fail; 2005 Sep; 11(7):498-503. PubMed ID: 16198244
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Significance of plasma levels of N-terminal Pro-B-type natriuretic peptide on left ventricular remodeling in non-obstructive hypertrophic cardiomyopathy attributable to the Asp175Asn mutation in the alpha-tropomyosin gene.
    Magga J; Sipola P; Vuolteenaho O; Risteli J; Jääskeläinen P; Peuhkurinen K; Kuusisto J
    Am J Cardiol; 2008 Apr; 101(8):1185-90. PubMed ID: 18394456
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Soluble ST2 protein in the short-term prognosis after hospitalisation in chronic systolic heart failure.
    Wojtczak-Soska K; Sakowicz A; Pietrucha T; Lelonek M
    Kardiol Pol; 2014; 72(8):725-34. PubMed ID: 24846354
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Plasma B-type natriuretic peptide levels in systolic heart failure: importance of left ventricular diastolic function and right ventricular systolic function.
    Troughton RW; Prior DL; Pereira JJ; Martin M; Fogarty A; Morehead A; Yandle TG; Richards AM; Starling RC; Young JB; Thomas JD; Klein AL
    J Am Coll Cardiol; 2004 Feb; 43(3):416-22. PubMed ID: 15013124
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Head to head comparison of N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in patients with/without left ventricular systolic dysfunction.
    Vanderheyden M; Bartunek ; Claeys G; Manoharan G; Beckers JF; Ide L
    Clin Biochem; 2006 Jun; 39(6):640-5. PubMed ID: 16516185
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Change in plasma N-terminal pro-brain natriuretic peptide in children with Kawasaki disease and its value in clinical practice].
    Zhang QY; Du JB; Chen YH; Li WZ
    Zhonghua Er Ke Za Zhi; 2006 Dec; 44(12):886-90. PubMed ID: 17254452
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.